Table 5.
Blastic morphology
| Basic markers |
New/additional markers |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| CD20 | CD5 | CyclinD1 | CD23 | Tdt | CD10 | Pax-5 | CD2 | CD34 | |
| B-ALL/LBL | −/+ | − | − | − | + | + | + | − | + |
| T-ALL/LBL | − | + | − | − | + | + | − | + | + |
| MCL blastoid variant | + | + | + | − | − | − | + | − | − |
| FL blastic morphology | + | − | − | + | − | + | + | − | − |
+, >50%; –, >5%; −/+, 5–25%; +/− 25–50%; ALL/LBL – Acute lymphocytic leukemia/lymphoblastic lymphoma; MCL – Mantle cell lymphoma; FL – Follicular lymphoma; Caveat: AML and CD56 hematodermic neoplasm are other two tumors in the differential diagnosis